Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma
NCT ID: NCT03266757
Last Updated: 2019-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2016-02-11
2018-02-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
NCT03673423
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
NCT01458717
Study of NAC of GA Therapy for Patients With BRPC
NCT02926183
Early Recurrence After Surgery for Pancreatic Cancer
NCT07241676
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
NCT02749136
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with ductal pancreatic adenocarcinoma (Borderline resectable or resectable or advanced)
* Patients that are alive and under treatment or follow up
* Signed informed consent (ICF)
Exclusion Criteria
* Pancreatic adenocarcinoma due to metastasis from other primary tumor(s)
* Neuroendocrine or other pancreatic carcinoma other than ductal adenocarcinoma
* Patients who refuse to provide informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hellenic Society of Medical Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N/A-NI-PANC-HeSMO-005490
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.